Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6552W HIGH $5.64
Volume
8.60 K
Value Traded
4.68 K
Short % Float
0.1%
Days to Cover
1.0
-20.3%Week
-30%1 Month
-42.91%3 Month
-55.89%6 Month
-82.76%5 Year
-99.9%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.96 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
2.46 M
Float Shares
4.14 M
Insiders
2.46%
Institutions
0.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XTLB Catalyst Timeline
Dated clinical, regulatory and corporate events for XTL Biopharmaceuticals Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for XTL Biopharmaceuticals Ltd.
49Total events
2Upcoming
14Tier-1 (high impact)
2008 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Milestone Payment
Subscribe to view catalyst details
Event history 46
▼Reverse Stock SplitCorporate
ADS Ratio Change from 1:100 to 1:400 (effective as one-for-four reverse ADS split)
▼Going ConcernCorporate
Received Staff delisting determination from Nasdaq due to public shell status
◆Equity OfferingCorporate
Proposed private placement of up to US$2,000,000 contingent on NeuroNOS transaction
▼Equity OfferingCorporate
Notified of non-compliance with minimum $2.5M stockholders' equity requirement
◆AcquisitionCorporate
XTL acquires 85% of NeuroNOS
Autism Spectrum Disorder, Phelan-McDermid Syndrome, Glioblastomasource ↗
◆Equity OfferingCorporate
Private placement of up to US$1.0 million in convertible debentures
▼Reverse Stock SplitCorporate
Nasdaq minimum bid price deficiency notice received; company may consider reverse stock split to regain compliance
●Quarterly UpdateCorporate
Condensed interim unaudited consolidated financial statements as of June 30, 2022
◆Quarterly UpdateCorporate
Extraordinary General Meeting of Shareholders to approve CEO employment terms
◆Full ResultshCDR1Clinical Data
Final data for SLE Phase 2b trial
Systemic Lupus Erythematosus (SLE)source ↗
●Last Patient Last VisithCDR1Trial
Last patient in for SLE Phase 2b trial
Systemic Lupus Erythematosus (SLE)source ↗
◆Topline ReadouthCDR1Clinical Data
Interim analysis for SLE Phase 2b trial
Systemic Lupus Erythematosus (SLE)source ↗
◆Full ResultshCDR1Clinical Data
Clinical data for Sjogren's Syndrome Phase 2 trial
Sjogren's Syndrome (SS)source ↗
▼Equity OfferingCorporate
Registered direct offering of 1,000,000 ADSs at $2.50 per ADS for gross proceeds of $2.5 million
▲IND ClearancehCDR1IND
IND approval for Sjogren's Syndrome Phase 2 trial
Sjogren's Syndrome (SS)source ↗
▲Trial InitiationhCDR1Trial
Phase 2 trial initiation for Sjogren's Syndrome (first patient dosed)
Sjogren's Syndrome (SS)source ↗
▲FDA Feedback ReceivedhCDR1FDA Meeting
FDA written response with guidance on Phase 2 trial design for SLE
Systemic Lupus Erythematosus (SLE)source ↗
▲Patent GrantedhCDR1IP / Competition
Filed two new U.S. patent applications for SLE treatment
Systemic Lupus Erythematosus (SLE)source ↗
▲Partnership / LicenseCorporate
XTL obtained exclusive license from Yeda Research and Development Co. for hCDR 1
Systemic Lupus Erythematosus (SLE)source ↗
Past FDA Catalysts and PDUFA Decisions
How XTLB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every XTLB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XTLB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in XTLB for Q2 2026. | ||||
XTLB Institutional Ownership Trends
XTLB Short Interest
Shares sold short, counted twice a month.
0.1%
Short % of Float
of tradable shares sold short
4.2K
Shares Sold Short
-30.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
10.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XTLB ranks across every disease it competes in
Competitive Position is a premium feature
See how XTLB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXTLB News
-XTLB
Jun 30, 2026▼ -8.8%on this news
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Biopharmaceuticals has completed the acquisition of Psyga Bio Ltd., marking a strategic shift towards psychedelic medicine. This acquisition grants XTL access to a robust clinical pipeline and a unique IP library focused on treating severe mental health disorders. The company is well-positioned to capitalize on favorable regulatory changes in the U.S. that support psychedelic research and development.
Read more →-XTLB
May 22, 2026XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Ltd. has received a delisting notice from Nasdaq due to its failure to file the Annual Report for 2025. The company is already under review for not meeting minimum equity and bid price requirements. XTL intends to request an extension for the suspension of its securities by May 26, 2026, but faces uncertainty regarding the Panel's decision.
Read more →-XTLB
May 15, 2026NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MONDAY, JUNE 22, 2026 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting
XTL Biopharmaceuticals Ltd. has scheduled an Extraordinary General Meeting for June 22, 2026, to discuss key agenda items including the acquisition of a controlling interest in Psyga Bio Ltd. and a private placement of up to $1.5 million. Shareholders will also vote on increasing the company's authorized share capital significantly and appointing new auditors. The company invites shareholders to attend in person or via proxy voting to partake in these crucial decisions.
Read more →-XTLB
Apr 29, 2026▲ +54.8%on this news· ran to +70% by day 1
SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this " Agreement ") made effective as of [ ], 2026 (the " Effective Date "), by and among the current shareholders of the Company listed in Exhibit A attached heret
XTL Biopharmaceuticals Ltd. has entered into a share purchase agreement to acquire 100% of the shares of Psyga Bio Ltd. This agreement, effective from a future date in 2026, stipulates that the current shareholders of Psyga will sell a total of 338,990 Ordinary Shares to XTL. The acquisition is expected to result in Psyga becoming a wholly-owned subsidiary of XTL, pending approvals from the relevant boards and committees as mandated by Israeli law.
Read more →-XTLB
Apr 29, 2026▲ +54.8%on this news· ran to +70% by day 1
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals has announced the acquisition of Psyga Bio, a company specializing in psychedelic therapeutics. This move aims to establish XTL as a key player in the expanding psychedelic market, supported by Psyga's clinical pipeline of seven approved Phase 2a trials and a licensed GMP-ready manufacturing facility. The transaction involves a share exchange that will significantly alter XTL's shareholder structure, and is influenced by recent regulatory advancements in the U.S. regarding psychedelic therapies. The deal also includes provisions for milestone-based equity incentives pending clinical trial achievements.
Read more →-XTLB
Mar 23, 2026XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio, effective March 25, 2026. The new ratio will be one ADS for every 400 ordinary shares, resulting in a reverse split. This change aims to increase the trading price of ADSs, although no guarantees are provided. No fees will be incurred by ADS holders during this process.
Read more →-XTLB
Mar 2, 2026XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Ltd. has received a delisting determination from Nasdaq due to its classification as a 'public shell.' The company plans to appeal this decision through a hearing, which will temporarily halt the delisting process. The Nasdaq Staff cited the company's lack of an operating business and failure to meet financial requirements as reasons for the delisting.
Read more →-XTLB
Jan 30, 2026XTL Update on Recent Developments
XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc. after signing a Binding Letter of Intent. A shareholders meeting is set for February 17, 2026, to discuss a private placement aimed at addressing compliance with Nasdaq's equity requirements. However, there are uncertainties regarding the acquisition's completion and shareholder approval.
Read more →-XTLB
Jan 26, 2026▼ -10.1%on this news· ran to -21% by day 3
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the minimum stockholders' equity requirement for continued listing. The company reported a deficit of $47,000 in its equity. XTL has 45 days to submit a plan to regain compliance, and it is currently evaluating options to address this issue.
Read more →-XTLB
Jan 13, 2026▲ +56.7%on this news
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a company focusing on disease-modifying therapies for Autism Spectrum Disorder. This strategic move aims to address the critical unmet medical need for autism treatments, as no FDA-approved options currently exist. The acquisition includes a team of Nobel Laureates and secured FDA Orphan Drug designations for related conditions, signaling a strong commitment to advancing autism therapeutics.
Read more →-XTLB
Jan 13, 2026▲ +56.7%on this newsshared move
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 17, 2026 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of
XTL Biopharmaceuticals Ltd. has announced an Extraordinary General Meeting (EGM) set for February 17, 2026, in Tel Aviv, Israel. The agenda includes proposals to increase the authorized share capital by 1.45 billion shares and to re-elect Ms. Iris Shapira Yalon as an external director. The company also seeks approval for a private placement of securities amounting to up to $2 million, contingent upon a transaction involving NeuroNOS Ltd.
Read more →-XTLB
Jan 13, 2026▲ +56.7%on this newsshared move
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has agreed to acquire 85% of NeuroNOS, a subsidiary focused on developing therapies for Autism Spectrum Disorder (ASD). This acquisition includes notable scientific leadership, featuring two Nobel Laureates and an established founder in autism research. The deal aims to address significant unmet medical needs, as no FDA-approved disease-modifying treatments currently exist for autism. XTL is positioned to become a key player in this market, with financial commitments aimed at advancing NeuroNOS's innovative programs.
Read more →-XTLB
Dec 24, 2025XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd. received a notification from Nasdaq indicating it does not meet the minimum bid price requirement of $1 per share. The company has 180 days to comply, during which its shares will continue to trade. XTL may seek an extension for compliance if necessary, but there are no guarantees of success in regaining compliance with Nasdaq listing standards.
Read more →-XTLB
Jun 18, 2025NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (
XTL Biopharmaceuticals Ltd. has announced an Annual and Extraordinary General Meeting for shareholders on July 21, 2025, at their legal offices in Bnei Brak, Israel. The agenda includes discussions on financial statements, re-appointment of auditors, and potential grants of stock options. Shareholders must be registered by June 18, 2025, to vote at the meeting. The Board of Directors recommends voting in favor of the items on the agenda.
Read more →-XTLB
Apr 7, 2025▼ -11.4%on this news
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer. Band brings significant experience from his previous roles in technology and digital marketing. His leadership is expected to drive the company towards new opportunities and enhance operational excellence. The Board expresses confidence in his ability to contribute to the company's growth.
Read more →-XTLB
Aug 14, 2024XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Biopharmaceuticals Ltd. has completed the acquisition of The Social Proxy, an AI web data company, enhancing its IP portfolio. The transaction involved a private placement of $1.5 million, allowing XTL to support Social Proxy's growth. Social Proxy will operate as a wholly owned subsidiary, with its shareholders joining XTL's board of directors.
Read more →About XTL Biopharmaceuticals Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next XTLB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime